SCHEMBL359515

SCHEMBL359515

CNC1=CC(=O)c2c(OC)ccc(OC)c2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
KDM4E B2RXH2 2/20 0.48
HTT P42858 2/20 0.48
MAPK1 P28482 2/20 0.48
RAB9A P51151 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
S1PR4 O95977 1/20 0.48
HSP90AA1 P07900 1/20 0.48
G6PD P11413 1/20 0.48
S1PR1 P21453 1/20 0.48
OPRK1 P41145 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
MCL1 Q07820 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
TLR9 Q9NR96 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484804 0.81 SOAT1 (0.50) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL15732826 0.79 SOAT1 (0.51) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL15733049 0.77 SOAT1 (0.56) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL5820458 0.76 MAPT (0.53) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL30004035 0.76 MAPT (0.53) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL23271796 0.76 MAPT (0.64) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL30003449 0.76 MAPT (0.64) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL15733152 0.76 SOAT1 (0.56) MAPTKDM4EHTTMAPK1RAB9A
SCHEMBL368936 0.75 SOAT1 (0.57) HTTMAPK1ALDH1A1SOAT1APAF1
SCHEMBL358215 0.75 SOAT1 (0.57) HTTMAPK1ALDH1A1SOAT1APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3182129-B1 METHOD OF SCREENING A THERAPEUTIC AGENT FOR K-RAS MUTANT CANCER RAND BIO SCIENCE INC (KR) 2018-12-26 EP disclosed
EP-3182129-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT RAND Bio Science Inc. (KR) 2017-06-21 EP disclosed
US-9400281-B2 Method of screening of therapeutic agents for K-Ras mutant driven cancers PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2016-07-26 US disclosed
US-20140147866-A1 COMPOUND FOR INHIBITING SNAIL-P53 BINDING AND THERAPEUTIC AGENT FOR CANCER INCLUDING THE COMPOUND AS EFFECTIVE COMPONENT THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) 2014-05-29 US disclosed
US-20120015960-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) 2012-01-19 US disclosed
EP-2377849-A2 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT Pusan National University Industry-University Cooperation Foundation (KR) 2011-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015960-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT TP53, TP53BP1, KRAS MAPT 1592/4885KDM4E 4258/4885HTT 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.